Wednesday, July 8, 2026

pharma · Acute Myeloid Leukemia · Acute Leukemia · ATNM

Actinium Pharmaceuticals

Actinium Pharmaceuticals clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

New York, USA HQ
2000 Founded
58 Employees
Public company Type
ATNM · NYSE Ticker
Company details
Status
Public
HQ
New York, USA
Founded
2000
Employees
58
Programs
8
Drugs
4
Patents
20
Intelligence · Clinical Programs

Actinium Pharmaceuticals projects

3 ClinicalTrials.gov programs sponsored by Actinium Pharmaceuticals.

Actinium Pharmaceuticals has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 131I-apamistmab

    Actinium Pharmaceuticals

    Sickling Disorder Due to Hemoglobin S

    phase 1 small molecule active

    1 trial
  2. ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

    Actinium Pharmaceuticals

    Leukemia

    phase 1 mab completed

    1 trial
  3. Lintuzumab AC 225

    Actinium Pharmaceuticals

    Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Actinium Pharmaceuticals have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.